This helps reduce GI side effects such as nausea, vomiting, constipation, and diarrhea
Results on the long term efficacy, safety, and tolerability, from ongoing Phase III clinical trials will impact the therapeutic prospects and future directions of incretin-based agonist therapy
Consistent with earlier studies, side effects emerged as the most commonly cited reason for discontinuation, regardless of medication indication
(2023) intended to assess the impact of the aminoglycoside antibiotic amikacin (AMI) and the loop diuretic furosemide (FUR) on the reduction of the mouse models hearing threshold
GLP-1 agonists: Who do they work for
Studies in humans have also confirmed that consuming fat and sugar simultaneously promotes overeating (Hedrih, 2024), likely due to increased reward responses from separate neural gut-brain pathways activated by sugar and fat (McDougle et al., 2024)